Willingness-to-pay for cancer treatment and outcome: a systematic review
- PMID: 34853930
- DOI: 10.1007/s10198-021-01407-9
Willingness-to-pay for cancer treatment and outcome: a systematic review
Abstract
Background: Understanding patient preferences in cancer management is essential for shared decision-making. Patient or societal willingness-to-pay (WTP) for desired outcomes in cancer management represents their preferences and values of these outcomes.
Objective: The aim of this systematic review is to critically evaluate how current literature has addressed WTP in relation to cancer treatment and achievement of outcomes.
Methods: Seven databases were searched from inception until 2 March 2021 to include studies with primary data of WTP values for cancer treatments or achievement of outcomes that were elicited using stated preference methods.
Results: Fifty-four studies were included in this review. All studies were published after year 2000 and more than 90% of the studies were conducted in high-income countries. Sample size of the studies ranged from 35 to 2040, with patient being the most studied population. There was a near even distribution between studies using contingent valuation and discrete choice experiment. Based on the included studies, the highest WTP values were for a quality-adjusted life year (QALY) ($11,498-$589,822), followed by 1-year survival ($3-$198,576), quality of life (QoL) improvement ($5531-$139,499), and pain reduction ($79-$94,662). Current empirical evidence suggested that improvement in QoL and pain reduction had comparable weights to survival in cancer management.
Conclusion: This systematic review provides a summary on stated preference studies that elicited patient preferences via WTP and summarised their respective values. Respondents in this review had comparable WTP for 1-year survival and QoL, suggesting that improvement in QoL should be emphasised together with survival in cancer management.
Keywords: Cancer treatment; Contingent valuation; Discrete choice experiment; Quality of life; Stated preference; Systematic review; Willingness to pay.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment.Qual Life Res. 2024 Mar;33(3):753-765. doi: 10.1007/s11136-023-03562-3. Epub 2023 Dec 11. Qual Life Res. 2024. PMID: 38079024
-
Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000. Pharmacoeconomics. 2009. PMID: 19908925
-
Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients.Value Health. 2021 Aug;24(8):1182-1192. doi: 10.1016/j.jval.2021.01.012. Epub 2021 Apr 29. Value Health. 2021. PMID: 34372984
-
Determinants of willingness to pay for health services: a systematic review of contingent valuation studies.Eur J Health Econ. 2022 Dec;23(9):1455-1482. doi: 10.1007/s10198-022-01437-x. Epub 2022 Feb 15. Eur J Health Econ. 2022. PMID: 35166973 Free PMC article.
-
Eliciting Preferences in Dentistry with Multiattribute Stated Preference Methods: A Systematic Review.JDR Clin Trans Res. 2018 Oct;3(4):326-335. doi: 10.1177/2380084418780324. Epub 2018 Jun 1. JDR Clin Trans Res. 2018. PMID: 30931788
Cited by
-
Economic Perspective of Cancer Care and Its Consequences for Vulnerable Groups.Cancers (Basel). 2022 Jun 28;14(13):3158. doi: 10.3390/cancers14133158. Cancers (Basel). 2022. PMID: 35804928 Free PMC article. Review.
-
Disparities in healthcare expenditures according to economic status in cancer patients undergoing end-of-life care.BMC Cancer. 2022 Mar 22;22(1):303. doi: 10.1186/s12885-022-09373-y. BMC Cancer. 2022. PMID: 35317774 Free PMC article.
-
Views and opinions of the general public about the reimbursement of expensive medicines in the Netherlands.PLoS One. 2025 Jan 8;20(1):e0317188. doi: 10.1371/journal.pone.0317188. eCollection 2025. PLoS One. 2025. PMID: 39774515 Free PMC article.
-
A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society.BMC Med. 2022 Sep 26;20(1):320. doi: 10.1186/s12916-022-02516-9. BMC Med. 2022. PMID: 36156186 Free PMC article.
-
What Next for the Science of Patient Preference? Interoperability, Standardization, and Transferability.Patient. 2025 Mar;18(2):101-108. doi: 10.1007/s40271-025-00727-9. Epub 2025 Jan 28. Patient. 2025. PMID: 39873903 Review.
References
-
- Wang, H., Naghavi, M., Allen, C., Barber, R.M., Bhutta, Z.A., Carter, A., et al.: Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 388(10053), 1459–1544 (2016). https://doi.org/10.1016/S0140-6736(16)31012-1 - DOI
-
- Knaul, F.M., Farmer, P.E., Krakauer, E.L., De Lima, L., Bhadelia, A., Jiang Kwete, X., et al.: Alleviating the access abyss in palliative care and pain relief—an imperative of universal health coverage: the Lancet Commission report. The Lancet. 391(10128), 1391–1454 (2018). https://doi.org/10.1016/s0140-6736(17)32513-8 - DOI
-
- Yabroff, K.R., Lund, J., Kepka, D., Mariotto, A.: Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol. Biomark. Prev. 20(10), 2006–2014 (2011). https://doi.org/10.1158/1055-9965.EPI-11-0650 - DOI
-
- Luengo-Fernandez, R., Leal, J., Gray, A., Sullivan, R.: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 14(12), 1165–1174 (2013). https://doi.org/10.1016/S1470-2045(13)70442-X - DOI - PubMed
-
- Rocque, G.B., Rasool, A., Williams, B.R., Wallace, A.S., Niranjan, S.J., Halilova, K.I., et al.: What is important when making treatment decisions in metastatic breast cancer? A qualitative analysis of decision-making in patients and oncologists. Oncologist. 24(10), 1313–1321 (2019). https://doi.org/10.1634/theoncologist.2018-0711 - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical